Please login to the form below

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.

Roche's Actemra/RoActemra receives new European approval

Roche's Actemra/RoActemra receives new European approval. EU regulators also pass the Swiss pharma firm’s Gazyvaro. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition
Ocrevus off to a flying start as Roche raises 2017 forecasts

Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Manufacturing issues scupper Sanofi's sarilumab launch plans

Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Roche snags pair of FDA breakthrough designations

Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Opening up innovation

If approved it will compete with the likes of Roche's RoActemra (tocilizumab). “

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
Brand leaders in RA will lose market share, predict rheumatologists

market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Multi-Channel Account Managers - Road / Homebased – Full or Part...: Competitive salary

Home based, Senior Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape: Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth: Creativity has lost its worth, and sadly it is undermining effectiveness...